Ernexa Therapeutics Inc.ERNANASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +854.90% | -94.12% | -100.00% | -100.00% | -100.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | -100.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.00% | +849.83% | +886.34% | -4.27% | +52.05% |
| Weighted Average Shares Diluted Growth | +0.00% | +849.83% | +886.34% | -4.27% | +52.05% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -89.47% | +2.82% | -55.56% | -32.46% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -85.23% | -89.28% | -89.81% | -83.69% | -20.03% |
| Book Value per Share Growth | +0.00% | -91.98% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -18.66% | -98.37% | -93.93% | -98.79% | -98.35% |
| R&D Expense Growth | -31.30% | -4.30% | -10.22% | +15.10% | +3.40% |
| SG&A Expenses Growth | -15.03% | -65.82% | -62.35% | -64.96% | -71.67% |